TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03236558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Ten cc of peripheral blood will be taken from patients and healthy controls as soon as possible after T1D diagnosis of the former.
Study: NCT00797732

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Study: NCT02956161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation of up-phase of sleep slow oscillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Random stimulation of up phase of sleep slow oscillation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No stimulation
Study: NCT01789970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER
Description: During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocodone ER
Description: During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Study: NCT00927771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelaic acid gel
Description: azelaic acid 15% gel twice a day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroquinone cream
Description: hydroquinone 4% cream twice a day for 6 months
Study: NCT03597932

Intervention type: DEVICE
Intervention: standardized handover checklist
Description: Following a review of relevant literatures and guidelines, a checklist consisting of the various key items necessary for giving continuing and safe intraoperative patient care was designed and validated by anesthesia residents and staff. Following 2-week to 1-month baseline data collection, each anesthesiologists and anesthesia residents in participating hospitals were asked to implement the safe-anesthesia checklist to improve practice over another 2-week to 1-month period. The checklist consists of an oral confirmation and closed-loop communication between the primary anesthesiologist and the replacement anesthesiologist. Evaluation of the effect of implementation of a standardized checklist during anesthesia care handover on patient safety during follow-up.
Study: NCT01926782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for alirocumab)
Description: Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for alirocumab)
Description: Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin
Description: Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
Study: NCT03177083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon beta-1a
Description: SC every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon beta-1a
Description: Per Summary of Product Characteristics (SMPC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon beta-1b
Description: Per SMPC
Study: NCT02424526

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home-based treadmill training
Description: the child will walk on a pediatric treadmill with the help of the parent/caregiver and with weekly supervision of a physical therapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home-based treadmill training
Description: the child will walk on a pediatric treadmill with the help of the parent/caregiver and with weekly supervision of a physical therapist

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Study: NCT01472497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: pioglitazone (15mg) once a day for 24 weeks
Study: NCT00778037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine hydrochloride 10 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine hydrochloride 10 mg tablet
Study: NCT02296398

Intervention type: DRUG
Intervention: Romidepsin
Description: Received romidepsin per standard of care or through a clinical trial for more than one cycle
Study: NCT02465073

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NXTSC wound gel
Description: Subjects will receive NXTSC wound gel only.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NXTSC wound gel plus Standard of Care
Description: Subjects will be randomized to the NXTSC wound gel plus Standard of Care of only.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Group
Description: Subjects will receive Standard of Care only.
Study: NCT01999283

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Group Exercise
Description: Yoga poses and postures modified to diminish stress on the cervical region and improve flexibility. Breathing and mind-body focus to address stress-related discomfort. A general Hatha yoga style will be used with components from Ashtanga Yoga. Intensity and range of motion will be progressively increased as tolerated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates Group Mat Exercise
Description: The Pilates mat exercises focus on both spinal muscle activation and stability, progressive endurance of the stabilizing muscles with arm and leg challenges and dynamic mobility. The exercises are progressed from more supported to anti-gravity position, slow increases in arm weights and flexibility.
Study: NCT00522587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed sevoflurane dose 1
Description: Dose 1 of sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed sevoflurane dose 2
Description: Dose 2 of sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed sevoflurane dose 3
Description: Dose 3 of sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed sevoflurane dose 4
Description: Dose 4 of sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed sevoflurane dose 5
Description: Dose 5 of sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed sevoflurane dose 6
Description: Dose 6 of sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed remifentanil dose 1
Description: Dose 1 of remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed remifentanil dose 2
Description: Dose 2 of remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed remifentanil dose 3
Description: Dose 3 of remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed remifentanil dose 4
Description: Dose 4 of remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed remifentanil dose 5
Description: Dose 5 of remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed remifentanil dose 6
Description: Dose 6 of remifentanil
Study: NCT01479543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic CNCM I-4034
Description: Probiotic CNCM I-4034 in a concentration of 9x10E9 cfu (colony forming unit) per day during 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic CNCM I-4035
Description: 9x10E9 cfu (colony forming unit) per day during 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic CNCM I-4036
Description: 9x10E9 cfu (colony forming unit) per day during 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics CNCM I-4035 and CNCM I-4036
Description: 9x10E9 cfu (colony forming unit) per day during 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule for 28 days.
Study: NCT01957358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Grief Recovery Method
Description: The Grief Recovery Method is a structured process designed to help people with spinal cord injuries examine their knowledge of their injury, their emotional reaction to their injury, and their ability to acknowledge their grief over the injury in order to learn techniques to resolve the grief in order to achieve a more complete recovery. Participants will attend a total of 18 sessions, some one-on-one, and some in a group setting. The Grief Recovery Handbook, handouts, DVD (digital video disc) presentations and questionnaires will be used. Targeted activities to decrease isolation and assist volunteers to identify goals for recovery will be utilized.
Study: NCT01109784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: prasugrel 10 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: clopidogrel per os 150mg/day
Study: NCT03099889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical activity intervention based upon stage of change and social cognitive theory based interventions
Study: NCT02230280

Intervention type: OTHER
Group type: OTHER
Intervention: Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention that Includes a Mobile Health Solution
Description: Participants will be offered regular in-home visits over the 6-month study period in addition to usual outpatient rehabilitation services. The health care providers will have access to a mobile health application (MYST) to share real-time information and access community resources and best practice guidelines.
Study: NCT02936700

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation
Description: relaxation program consists of 7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT therapy
Description: 7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants. The ACT program aims at~* decreasing the tendency to try to escape unpleasant mental experiences~* increasing psychological flexibility~* developing acceptance of psychological events and engagement in valued actions
Study: NCT04338958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment
Study: NCT03361397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Lidocaine hydrochloride will be used via mask nebulizer before LMA insertion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: Distilled Water will be used via mask nebulizer before LMA insertion
Study: NCT01888042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg (1 tablet of 10 mg)
Study: NCT01127724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin B12 treatment
Description: Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin B12 treatment
Description: Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin B12 treatment
Description: Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
Study: NCT04029519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PN40082
Description: PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
Study: NCT04253275

Intervention type: GENETIC
Group type: OTHER
Intervention: blood samples
Description: Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls.~Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls.

Intervention type: GENETIC
Group type: OTHER
Intervention: blood samples
Description: Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls.~Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls.

Intervention type: GENETIC
Group type: OTHER
Intervention: blood samples
Description: Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls.~Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI without injection
Description: MRI at inclusion for controls
Study: NCT03643380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AHLeveeS System
Description: AHLeveeS System for treatment of overactive bladder
Study: NCT04251637

Intervention type: OTHER
Intervention: Cardiac output monitoring with Starling SV.
Description: Intraoperative monitoring of cardiac output by esophageal Doppler, NICOM Starling SV and collection of values for each patient at at least 7 predefined intraoperative times.
Study: NCT02841215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin 200 µg/kg
Description: Oral ivermectin 200 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other) daily on skin (D0 to D28)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 400 µg/kg
Description: Oral ivermectin 400 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other)daily on skin (D0 to D28)
Study: NCT02585505

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stem cells
Description: stem cell will be injected

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stem cells
Description: stem cell will be injected

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stem cells
Description: stem cell will be injected
Study: NCT03828929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
Study: NCT01514227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin or thienopyridine
Description: Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is left on the physician's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and thienopyridine
Description: Subjects randomized 18 month DAPT will be prescribed both aspirin and thienopyridine (clopidogrel or ticlopidine) for 18 month after stenting.
Study: NCT00907101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)
Description: Apply once daily
Study: NCT00313209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 500 µg, once daily, oral administration in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT03572127

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: High protein diet derived from either animal or non-animal sources.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: High protein diet derived from either animal or non-animal sources.
Study: NCT02018627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeris glucagon
Description: The subject is given an injection of xeris glucagon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lilly glucagon
Description: The subject is given an injection of lilly glucagon
Study: NCT04538794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-0159
Description: Administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administered intravenously
Study: NCT03344302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: intravenous infusion of oxytocin 30 units over 5 minutes diluted into 500 mL of normal 0.9% sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intravenous infusion of oxytocin 30 units over 5 minutes diluted into 500 mL of normal 0.9% sodium chloride
Study: NCT02436876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBN-101
Description: MBN-101 is a locally administered, anti-infective drug product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBN-101
Description: MBN-101 is a locally administered, anti-infective drug product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBN-101
Description: MBN-101 is a locally administered, anti-infective drug product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient
Study: NCT03901950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW7201 tablets
Description: A wnt pathway inhibitor
Study: NCT03017170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dried Cranberry
Description: Dried cranberry powder is not an extract of cranberries, but a full spectrum ingredient. It is comprised of a proprietary ratio of dried cranberry fruit, cranberry pomace, and cranberry seeds, each of which is a recognized food and/or dietary ingredient. One 500 mg capsule of dried cranberry powder consists of approximately 25 grams of cranberry fruit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Colored Maltodextrin: Proprietary mixture of: maltodextrin and food grade colors
Study: NCT00193895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will commence with a dose calculated to target an AUC of 2.0. A maximum of 6 doses of weekly Carboplatin will be given. Carboplatin will be administered intravenously over 20-30 minutes prior to radiation therapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 60 Gy OR 66Gy in 2Gy/fraction 5days/week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 60 Gy OR 66Gy in 2Gy/fraction 5days/week
Study: NCT01297335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: Intrathecal Clonidine
Study: NCT02931721

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Pelvis MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Pelvis MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Pelvis MRI
Study: NCT01899235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug eluting balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug eluting stent
Study: NCT03436862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg IV infusion over 60 minutes given every 2 weeks for up to 6 months.